No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Teyi Pharmaceutical's Doxycycline Hydrochloride Tablets Pass Regulatory Evaluation
Teyi Pharmaceutical Group (002728.SZ): The pharmaceutical Doxycycline Hydrochloride Tablets have passed the consistency evaluation.
Gelonghui, February 27 - Teyi Pharmaceutical Group (002728.SZ) announced that the company recently obtained the "Approval Notice for Supplementary Application of hydrochloride doxycycline tablets" issued by the National Medical Products Administration. After review, the aforementioned pharmaceutical has passed the consistency evaluation for chemical generic drugs in quality and efficacy. The hydrochloride doxycycline tablets that passed the consistency evaluation are available in two specifications: 0.05g and 0.1g (among which, the 0.05g specification is the first to pass the consistency evaluation, and the 0.1g specification is the second to pass the consistency evaluation). Hydrochloride doxycycline tablets are mainly used for sensitive Gram-positive cocci and Gram-negative bacteria.
Teyi Pharmaceutical Group (002728.SZ) has repurchased a total of 2.48% of its shares at a cost of approximately 93.85 million yuan.
Teyi Pharmaceutical Group (002728.SZ) released an announcement, as of January 26, 2025, the company through the Shenzhen Stock Exchange...
Teyi Pharmaceutical: 2024 Annual Results Forecast
Teyi Pharmaceutical Group (002728.SZ): By the end of 2024, the inventory of cough relief tablets in the terminal channel has been largely consumed.
On January 14, Gelonghui reported that Teyi Pharmaceutical Group (002728.SZ) mentioned in a recent investor relations activity that after the relaxation of control policies in 2023, there has been a significant increase in the inventory of four types of medicines—cough relief, antipyretic, antibiotics, and anti-infection—among agents, pharmacies, and consumers compared to the previous year. In 2024, as the company organizes its sales channels for cough relief tablets, by the end of 2024, the inventory of cough relief tablets in terminal channels has been largely digested, laying a solid foundation for the future sales management of cough relief tablets across different specifications and channels.
Improved Earnings Required Before Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) Stock's 29% Jump Looks Justified
